Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on March 22, 2011. The filing discloses the appointment of a new senior executive officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Base Salary: $220,000 annually for the new appointee.
- Stock Options: Grant of up to 85,000 shares of common stock.
- Performance Bonus: Target amount of 25% of base salary, contingent on corporate and individual objectives.
Material Changes
The primary material change reported is the commencement of employment for Brandi L. Roberts as Vice President, Finance and Principal Accounting Officer on March 22, 2011. Patrick L. Keran, the President and Chief Operating Officer, will continue to serve as the Principal Financial Officer.
Outlook, Risks, and Management Commentary
Management commentary is limited to the background of the new appointee and the terms of her employment offer. No specific business outlook, risk factors, or contingencies regarding the company's operations are disclosed in this filing.
- Compensation Structure: The stock option award vests 25% on the first anniversary of employment, with the remainder vesting in equal monthly increments over the following three years.
- Performance Criteria: The incentive award is based on 2011 corporate performance objectives and individual goals determined by the Board of Directors.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 85,000 stock options granted to Ms. Roberts.
- Review the specific 2011 corporate performance objectives required to trigger the 25% target bonus.
- Confirm the total number of shares authorized under the 2008 Omnibus Incentive Plan to assess dilution impact.
- Check subsequent filings for any changes to the Principal Financial Officer role or additional executive appointments.